News on monday?
ORGANOVO HLDGS INC ONVO: 0,4179 +14,81%
Volume: 279.570
Avg. Volume 68,437
Organovo Holdings, Inc. (Nasdaq:ONVO), a clinical stage biotechnology company focused on developing novel treatment approaches in inflammatory bowel disease (IBD) including ulcerative colitis, today announces that its lead clinical stage drug, FXR314 will be featured in an oral presentation at The Liver Meeting, sponsored by the American Association for the Study of Liver Diseases (AASLD). The presentation, by Dr. Eric Lawitz of the Texas Liver Institute, will describe the findings from the FXR314 Phase 2 MASH study. The meeting will be held November 15-19, 2024 in San Diego, California.
Details include:
Presenter
Dr Eric Lawitz, Texas Liver Institute
Session Date / Time:
11/17/2024, 2:00 pm - 3:30 pm PST
Session Title:
MASLD and MASH - New Therapies
Type:
Abstract Parallel
Presentation Title:
PHARMACOKINETICS, SAFETY AND EFFICACY OF THE NOVEL NON-BILE ACID FXR AGONIST FXR314 IN PATIENTS WITH METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS: RESULTS FROM A PHASE 2 STUDY
Presentation Time:
3:00 pm - 3:15 pm PST
About Organovo
Organovo is a clinical stage biotechnology company that is developing drugs that are demonstrated to be effective in three-dimensional (3D) human tissues as candidates for drug development. The company's lead molecule, FXR314, is on the path for Phase 2 investigation in inflammatory bowel disease and has potential application in metabolic liver disease and oncology. The company has proprietary technology used to build 3D human tissues that mimic key aspects of native human tissue composition, architecture, function, and disease. For more information visit Organovo's website at www.organovo.com.
On September 30, 2024, Armistice Capital, LLC, a prominent investment firm, expanded its portfolio by adding 1,460,051 shares of Organovo Holdings Inc. This transaction, executed at a price of $0.509 per share, marks a significant increase in the firm's holdings in the biotechnology sector. Following this acquisition, Armistice Capital now holds a total of 1,460,051 shares in Organovo, representing a 9.99% ownership stake and a 0.01% position in the firm's overall portfolio